QTTB
Q32 Bio Inc.
There isn't enough reported data to score QTTB yet.
QTTB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Strong |
QTTB's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
QTTB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.4x | $8.37 | -5.2% |
| Current | 2.6x | $8.82 | โ |
| Fair | 2.9x | $10.05 | +14% |
| Expensive | 4.8x | $16.68 | +89% |
Historical ranges are pointers, not guarantees.
QTTB's PE is 2.5x, but its earnings don't support one, so it isn't a reliable read right now.
QTTB Forward outlook
There aren't enough analyst estimates for QTTB to show an outlook.
QTTB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$14.07 | +$26.61 |
| Q2 2024 | -$22.87 | +$18.17 |
| Q1 2024 | -$32.43 | +$6.81 |
| Q4 2023 | -$35.10 | -$33.48 |
| Q3 2023 | -$40.68 | -$38.16 |
| Q2 2023 | -$41.04 | -$39.42 |
| Q1 2023 | -$39.24 | -$37.08 |
| Q4 2022 | -$1.62 | +$29.52 |
QTTB has returned to profit: it earned $3.46 per share over the past year, after losing money the year before.
QTTB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $354K | -56% |
| Q1 2023 | $802K | 0% |
| Q4 2022 | $802K | 0% |
| Q3 2022 | $802K | -52% |
| Q2 2022 | $802K | -63% |
| Q1 2022 | $802K | -97% |
| Q4 2021 | $802K | -18% |
| Q3 2021 | $1.7M | +196% |
QTTB's revenue has slid since its 2021 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -8705% | -5176 points |
| Q1 2023 | -3430% | +1260 points |
| Q4 2022 | -4301% | -108 points |
| Q3 2022 | -4098% | -2269 points |
| Q2 2022 | -3530% | -2133 points |
| Q1 2022 | -4691% | -4687 points |
| Q4 2021 | -4193% | -1152 points |
| Q3 2021 | -1828% | +3158 points |
QTTB's operating margin was โ8705% last quarter, down 5176 points from the same quarter a year ago, near the bottom of its range since 2019.
QTTB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$6.3M | +$6.1M |
| Q4 2025 | -$6.2M | +$5.3M |
| Q3 2025 | -$4.2M | +$15.4M |
| Q1 2025 | -$12.5M | +$2.1M |
| Q4 2024 | -$11.4M | +$10.1M |
| Q3 2024 | -$19.6M | +$5.4M |
| Q2 2024 | -$22.2M | +$1.4M |
| Q1 2024 | -$14.6M | +$11.7M |
QTTB has burned cash in almost every quarter: โ$20M over the past year, against โ$66M the year before.
QTTB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -15.4x | Net Cash |
| Q2 2026 | -4.9x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.2x | Net Cash |
QTTB has more cash than debt.
QTTB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.1 | Neutral |
| Stochastic | 17.7 | Oversold |
QTTB's weekly RSI is 45 (neutral) and its Stochastic is 18 (oversold).
QTTB PE vs Healthcare Sector
| Metric | QTTB | Sector median | Relative |
|---|---|---|---|
| PE | 2.6x | 26x | 90% below |
| PE % | 20 | 29 | 9 pts below |
QTTB is trading at 2.5x earnings, a 90% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
QTTB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.56 | 3% above |
| 20 week MA | $11.7 | 25% below |
| 50 week MA | $8.31 | 6.1% above |
| 100 week MA | $5.29 | 67% above |
| 200 week MA | $14.3 | 38% below |
QTTB's trend is mixed: it's above three of its five weekly moving averages, and 38% below its 200-week average.
QTTB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $388.6 | $227.7 | -41% |
| 2021 | $227.7 | $74.5 | -67% |
| 2022 | $74.5 | $21.4 | -71% |
| 2023 | $21.4 | $10.9 | -49% |
| 2024 | $10.9 | $3.36 | -69% |
| 2025 | $3.36 | $3.20 | -4.8% |
| 2026 YTD | $3.20 | $8.82 | +176% |
QTTB has finished every year since 2020 lower, and it's up 176% so far in 2026.